{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:23:08Z","timestamp":1793290988644,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T00:00:00Z","timestamp":1658275200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.kint.2022.06.013","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T05:06:47Z","timestamp":1666156007000},"page":"990-999","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":268,"title":["Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence"],"prefix":"10.1016","volume":"102","author":[{"given":"Peter","family":"Rossing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Luiza","family":"Caramori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana C.N.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiddo J.L.","family":"Heerspink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clint","family":"Hurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamlesh","family":"Khunti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Liew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin D.","family":"Michos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sankar D.","family":"Navaneethan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wasiu A.","family":"Olowu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tami","family":"Sadusky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Tandon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine R.","family":"Tuttle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy G.","family":"Wilkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Zoungas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C.","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Tunnicliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello A.","family":"Tonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Earley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian H.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2022.06.013_bib1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","article-title":"Improving Global Outcomes Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease","volume":"98","author":"Kidney Disease","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2022.06.013_bib2","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","article-title":"GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology","volume":"64","author":"Guyatt","year":"2011","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.kint.2022.06.013_bib3","doi-asserted-by":"crossref","first-page":"977","DOI":"10.2337\/dc08-1908","article-title":"Effects of structured versus usual care on renal endpoint in type 2 diabetes: the SURE study: a randomized multicenter translational study","volume":"32","author":"Chan","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2022.06.013_bib4","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.3862","article-title":"Effect of a web-based management guide on risk factors in patients with type 2 diabetes and diabetic kidney disease: a JADE randomized clinical trial","volume":"5","author":"Chan","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.kint.2022.06.013_bib5","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(98)07368-1","article-title":"Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study","volume":"353","author":"Gaede","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2022.06.013_bib6","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S2213-8587(17)30327-3","article-title":"Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial","volume":"5","author":"Ueki","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kint.2022.06.013_bib7","doi-asserted-by":"crossref","unstructured":"de Boer IH, Khunti K, Sadusky T, et\u00a0al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. Published online October 3, 2022. https:\/\/doi.org\/10.2337\/dci22-0027","DOI":"10.2337\/figshare.20272404.v1"},{"key":"10.1016\/j.kint.2022.06.013_bib8","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.06.013_bib9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.06.013_bib10","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.06.013_bib11","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.06.013_bib12","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.06.013_bib13","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.06.013_bib14","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.06.013_bib15","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/ndt\/gfac040","article-title":"Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial","volume":"37","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2022.06.013_bib16","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.2215\/CJN.10140620","article-title":"Effects of canagliflozin in patients with baseline eGFR\u00a0<30 ml\/min per 1.73 m2: subgroup analysis of the randomized CREDENCE trial","volume":"15","author":"Bakris","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2022.06.013_bib17","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1681\/ASN.2021020167","article-title":"Effects of dapagliflozin in stage 4 chronic kidney disease","volume":"32","author":"Chertow","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2022.06.013_bib18","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.2337\/dc21-0300","article-title":"Efficacy and safety of dapagliflozin by baseline glycemic status: a prespecified analysis from the DAPA-CKD trial","volume":"44","author":"Persson","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2022.06.013_bib19","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2215\/CJN.18881220","article-title":"SGLT2 inhibitors in diabetic kidney disease","volume":"16","author":"Zoungas","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2022.06.013_bib20","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.06.013_bib21","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1053\/j.ackd.2012.12.006","article-title":"Direct and indirect effects of obesity on the kidney","volume":"20","author":"Alicic","year":"2013","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.kint.2022.06.013_bib22","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/03007995.2016.1251892","article-title":"Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects","volume":"33","author":"Bays","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.kint.2022.06.013_bib23","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000513869","article-title":"Association of obesity with cardiovascular risk factors and kidney disease outcomes in primary proteinuric glomerulopathies","volume":"145","author":"Shah","year":"2021","journal-title":"Nephron"},{"key":"10.1016\/j.kint.2022.06.013_bib24","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kint.2022.06.013_bib25","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.06.013_bib26","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.06.013_bib27","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium\u2013glucose cotransporter 2 inhibitor treatment: The FIDELITY Analysis","author":"Rossing","year":"2022","journal-title":"Diabetes Care. Published online August 15"},{"key":"10.1016\/j.kint.2022.06.013_bib28","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial","volume":"15","author":"Ito","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2022.06.013_bib29","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2215\/CJN.14751218","article-title":"Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria: a randomized, double-blind, placebo-controlled, phase ii trial","volume":"14","author":"Ito","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2022.06.013_bib30","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials","volume":"145","author":"Neuen","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2022.06.013_bib31","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1093\/eurheartj\/ehab497","article-title":"Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial","volume":"42","author":"Neuen","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.kint.2022.06.013_bib32","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.06.013_bib33","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.kint.2022.06.013_bib34","first-page":"S144","article-title":"10. Cardiovascular Disease and Risk Management","volume":"45","author":"Draznin","year":"2022","journal-title":"Standards of Medical Care in Diabetes\u20142022. Diabetes Care"},{"key":"10.1016\/j.kint.2022.06.013_bib35","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.kint.2022.06.013_bib36","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2022.06.013_bib37","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2215\/CJN.07820719","article-title":"Diabetic Kidney Disease Task Force of the American Society of Nephrology. Preserving kidney function instead of replacing it","volume":"15","author":"Kliger","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2022.06.013_bib38","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(20)32374-6","article-title":"The Lancet Commission on Diabetes: using data to transform diabetes care and patient lives","volume":"396","author":"Chan","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2022.06.013_bib39","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.2215\/CJN.18641120","article-title":"Transforming the care of patients\u00a0with diabetic kidney disease","volume":"16","author":"Brosius","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2022.06.013_bib40","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2215\/CJN.02980322","article-title":"Moving from evidence to implementation of breakthrough therapies for diabetic kidney disease. disease","volume":"17","author":"Tuttle","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2022.06.013_bib41","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s40261-022-01160-8","article-title":"Cost effectiveness of dapagliflozin added to standard of care for the management of diabetic nephropathy in the USA","volume":"42","author":"Abegaz","year":"2022","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.kint.2022.06.013_bib42","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s13300-022-01270-8","article-title":"Cost-effectiveness analysis of initiating type 2 diabetes therapy with a sodium-glucose cotransporter 2 inhibitor versus conventional therapy in Japan","volume":"13","author":"Igarashi","year":"2022","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.kint.2022.06.013_bib43","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1053\/j.ajkd.2021.09.014","article-title":"Cost-effectiveness of empagliflozin in patients with diabetic kidney disease in the United States: findings based on the EMPA-REG OUTCOME trial","volume":"79","author":"Reifsnider","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2022.06.013_bib44","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/j.jacc.2022.02.046","article-title":"Guidelines for cardiovascular risk reduction in patients with type 2 diabetes: JACC guideline comparison","volume":"79","author":"Kelsey","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S008525382200518X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S008525382200518X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T01:04:55Z","timestamp":1758762295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S008525382200518X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S008525382200518X"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2022.06.013","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2022.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2022.06.008","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 KDIGO, Kidney Disease: Improving Global Outcomes. Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}